title: Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.
abstract: BACKGROUND
  We studied the effect of dutasteride on bone mineral density (BMD) in aging male patients with lower urinary tract symptoms (LUTS) and prostatic enlargement.
  
  
  METHODS
  We prospectively studied 17 patients with LUTS and prostatic enlargement. Before and 1 year after dutasteride (0.5 mg daily), we assessed International Prostate Symptom Score (IPSS), prostatic volume (PV), serum prostatic-specific antigen (PSA) and testosterone. BMD in the lumbar and femur was measured by DEXA method.
  
  
  RESULTS
  Dutasteride significantly reduced PV (from 51 ± 24 to 34 ± 17 ml, p < 0.001) and improved IPSS (from 15.1 ± 9.8 to 11.7 ± 10.3, p < 0.05). Serum PSA was significantly decreased (from 3.2 ± 2.6 to 1.0 ± 0.8 ng/ml, p < 0.001), while serum testosterone "was not changed" significantly. BMD of the lumbar "was not changed" significantly after dutasteride. BMD of the femur was significantly improved (from 0.75 ± 0.14 to 0.82 ± 0.16 g/cm(2), p < 0.01). In nine patients whose testosterone was increased after dutasteride, BMD of the lumbar (from 1.18 ± 0.26 to 1.22 ± 0.25 g/cm(2), p < 0.05) and femur (from 0.76 ± 0.12 to 0.84 ± 0.16 g/cm(2), p < 0.05) was significantly improved.
  
  
  CONCLUSIONS
  Dutasteride has a potential to improve BMD with elevation of serum testosterone in aging male patients with LUTS and prostatic enlargement.
authors.affiliation: a Department of Renal and Urologic Surgery , Asahikawa Medical University , Asahikawa , Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Wada
authors.affiliation: a Department of Renal and Urologic Surgery , Asahikawa Medical University , Asahikawa , Japan.
authors.forename: Kazumi
authors.initials: K
authors.lastname: Hashizume
authors.affiliation: a Department of Renal and Urologic Surgery , Asahikawa Medical University , Asahikawa , Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Matsumoto
authors.affiliation: a Department of Renal and Urologic Surgery , Asahikawa Medical University , Asahikawa , Japan.
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Kakizaki
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects*; D000068538:Dutasteride / Q000627:therapeutic use*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D010865:Pilot Projects; D011446:Prospective Studies; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000178:diet therapy* / Q000473:pathology; D013739:Testosterone
chemical_list: D058891:5-alpha Reductase Inhibitors; D013739:Testosterone; D017430:Prostate-Specific Antigen; D000068538:Dutasteride
keywords: Benign prostatic hyperplasia; bone mineral density; dutasteride